**Articles**

1. Saper, M. A., Eldar, H., Mizuuchi, K., Nickol, J., Appella, E., and Sussman, J. L. (1986) Crystallization of a DNA tridecamer d(C-G-C-A-G-A-A-T-T-C-G-C-G). *J. Mol. Biol.* **188**, 111-113

2. Eldar, H., and Degani, H. (1989) 31P NMR studies of the thermodynamics and kinetics of the creatine kinase reaction. *Magn. Reson. Med.* **11**, 121-126

3. Eldar, H., Zisman, Y., Ullrich, A., and Livneh, E. (1990) Overexpression of protein kinase C alpha-subtype in Swiss/3T3 fibroblasts causes loss of both high and low affinity receptor numbers for epidermal growth factor. *J. Biol. Chem.* **265**, 13290-13296

4. Neeman, M., Eldar, H., Rushkin, E., and Degani, H. (1990) Chemotherapy-induced changes in the energetics of human breast cancer cells; 31P- and 13C-NMR studies. *Biochim. Biophys. Acta.* **1052**, 255-263

5. Seymour, A. M., Eldar, H., and Radda, G. K. (1990) Hyperthyroidism results in increased glycolytic capacity in the rat heart. A 31P-NMR study. *Biochim. Biophys. Acta.* **1055**, 107-116

6. Raber, J., Eldar, H., Lehrer, R., Chebath, J., and Livneh, E. (1991) Specific regulation of the 100 kDa 2-5 A synthetase by protein kinase C. *Eur Cytokine Netw* **2**, 281-290

7. Eldar, H., Ben-Chaim, J., and Livneh, E. (1992) Deletions in the regulatory or kinase domains of protein kinase C-alpha cause association with the cell nucleus. *Exp Cell Res* **202**, 259-266

8. Eldar, H., and Livneh, E. (1992) Phosphorylation of p90 and p52 in response to phorbol-esters in Swiss/3T3 cells overexpressing protein kinase C-alpha. *Mol. Biol. Cell.* **3**, 1049-1056

9. Greif, H., Ben-Chaim, J., Shimon, T., Bechor, E., Eldar, H., and Livneh, E. (1992) The protein kinase C-related PKC-L(eta) gene product is localized in the cell nucleus. *Mol. Cell. Biol.* **12**, 1304-1311

10. Eldar, H., Ben-Av, P., Schmidt, U. S., Livneh, E., and Liscovitch, M. (1993) Up-regulation of phospholipase D activity induced by overexpression of protein kinase C-alpha. Studies in intact Swiss/3T3 cells and in detergent-solubilized membranes in vitro. *J. Biol. Chem.* **268**, 12560-12564

11. Liscovitch, M., Ben-Av, P., Danin, M., Faiman, G., Eldar, H., and Livneh, E. (1993) Phospholipase D-mediated hydrolysis of phosphatidylcholine: role in cell signalling. *J. Lipid. Mediat.* **8**, 177-182

12. Slack, B. E., Nitsch, R. M., Livneh, E., Kunz, G. M., Jr., Breu, J., Eldar, H., and Wurtman, R. J. (1993) Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C alpha. *J Biol Chem* **268**, 21097-21101

13. Slack, B. E., Nitsch, R. M., Livneh, E., Kunz, G. M., Jr., Eldar, H., and Wurtman, R. J. (1993) Regulation of amyloid precursor protein release by protein kinase C in Swiss 3T3 fibroblasts. *Ann N Y Acad Sci* **695**, 128-131

14. Slack, B. E., Nitsch, R. M., Livneh, E., Kunz, G. M. J., Eldar, H., and Wurtman, R. J. (1993) Regulation of amyloid precursor protein release by protein kinase C in Swiss 3T3 fibroblasts. *Ann. N. Y. Acad. Sci.* **695**, 128-131

15. Fitzer-Attas, C., Eldar, H., Eisenbach, L., and Livneh, E. (1994) The expression of PDGF-alpha but not PDGF-beta receptors is suppressed in Swiss/3T3 fibroblasts over-expressing protein kinase C-alpha. *FEBS Lett.* **342**, 165-170

16. Seger, R., Seger, D., Reszka, A. A., Munar, E. S., Eldar-Finkelman, H., Dobrowolska, G., Jensen, A. M., Campbell, J. S., Fischer, E. H., and Krebs, E. G. (1994) Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. *J. Biol. Chem.* **269**, 25699-25709

17. Eldar-Finkelman, H., Seger, R., Vandenheede, J. R., and Krebs, E. G. (1995) Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. *J. Biol. Chem.* **270**, 987-990

18. Slack, B. E., Breu, J., Livneh, E., Eldar, H., and Wurtman, R. J. (1995) Phorbol ester stimulates choline uptake in Swiss 3T3 fibroblasts following introduction of the gene encoding protein kinase C alpha. *Biochem. J.* **305**, 621-626

19. Eldar-Finkelman, H., Argast, G. M., Foord, O., Fischer, E. H., and Krebs, E. G. (1996) Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells. *Proc.Nat.Acad.Sci. U.S.A.* **93**, 10228-10233

20. Eldar-Finkelman, H., and Krebs, E. G. (1997) Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. *Proc.Nat.Acad.Sci. U.S.A.* **94**, 9660-9664

21. Eldar-Finkelman, H., Schreyer, S. A., Shinohara, M. M., LeBoeuf, R. C., and Krebs, E. G. (1999) Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. *Diabetes* **48**, 1662-1666

22. Torres, M. A., Eldar-Finkelman, H., Krebs, E. G., and Moon, R. T. (1999) Regulation of ribosomal S6 protein kinase-p90(rsk), glycogen synthase kinase 3, and beta-catenin in early Xenopus development. *Molec.Cell.Biol.* **19**, 1427-1437

23. Zhao, A. Z., Shinohara, M. M., Huang, D., Shimizu, M., Eldar-Finkelman, H., Krebs, E. G., Beavo, J. A., and Bornfeldt, K. E. (2000) Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. *J. Biol.Chem.* **275**, 11348-11354

24. Hall, J. L., Chatham, J. C., Eldar-Finkelman, H., and Gibbons, G. H. (2001) Upregulation of glucose metabolism during intimal lesion formation is coupled to the inhibition of vascular smooth muscle cell apoptosis. Role of GSK3beta. *Diabetes* **50**, 1171-1179

25. Ilouz, R., Kaidanovidh, O., D.Gurwitz, and Eldar-Finkelman, H. (2002) Inhibition of glycogen synthase kinase-3b by bivalent zinc ions: insight into the insulin-mimetic action of zinc. *Biochem. Biophys. Res. Commun.* **295**, 102-106

26. Plotkin, B., Kaidanovich, O., Talior, I., and Eldar-Finkelman, H. (2003) Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. *J Pharmacol Exp Ther* **305**, 974-980

27. Talior, I., Yarkoni, M., Bashan, N., and Eldar-Finkelman, H. (2003) Increased glucose uptake promotes oxidative stress and PKC-{delta} activation in adipocytes of obese, insulin-resistant mice. *Am. J. Physiol. Endocrinol. Metab.* **285**, E295-E302

28. Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C. G., and Eldar-Finkelman, H. (2004) Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. *Biol Psychiatry* **55**, 781-784

29. Kirshenboim, N., Plotkin, B., Shlomo, S. B., Kaidanovich-Beilin, O., and Eldar-Finkelman, H. (2004) Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha. *J Mol Neurosci* **24**, 237-245

30. Liberman, Z., and Eldar-Finkelman, H. (2005) Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. *J Biol Chem* **280**, 4422-4428

31. Talior, I., Tennenbaum, T., Kuroki, T., and Eldar-Finkelman, H. (2005) PKC-delta-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase. *Am J Physiol Endocrinol Metab* **288**, E405-411

32. Eldar-Finkelman, H. (2006) Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley. *Expert Opin Ther Targets* **10**, 199-201

33. Ilouz, R., Kowalsman, N., Eisenstein, M., and Eldar-Finkelman, H. (2006) Identification of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition. *J Biol Chem* **281**, 30621-30630

34. Kaidanovich-Beilin, O., and Eldar-Finkelman, H. (2006) Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. *J Pharmacol Exp Ther* **316**, 17-24

35. Erez, A., Castiel, A., Trakhtenbrot, L., Perelman, M., Rosenthal, E., Goldstein, I., Stettner, N., Harmelin, A., Eldar-Finkelman, H., Campaner, S., Kirsch, I., and Izraeli, S. (2007) The SIL gene is essential for mitotic entry and survival of cancer cells. *Cancer Res* **67**, 4022-4027

36. Shapira, M., Licht, A., Milman, A., Pick, C. G., Shohami, E., and Eldar-Finkelman, H. (2007) Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. *Mol Cell Neurosci* **34**, 571-577

37. Caspi, M., Zilberberg, A., Eldar-Finkelman, H., and Rosin-Arbesfeld, R. (2008) Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. *Oncogene* **27**, 3546-3555

38. Ilouz, R., Pietrokovski, S., Eisenstein, M., and Eldar-Finkelman, H. (2008) New insights into the autoinhibition mechanism of glycogen synthase kinase-3beta. *J Mol Biol* **383**, 999-1007

39. Liberman, Z., Plotkin, B., Tennenbaum, T., and Eldar-Finkelman, H. (2008) Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue. *Am J Physiol Endocrinol Metab* **294**, E1169-1177

40. Sharfi, H., and Eldar-Finkelman, H. (2008) Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. *Am J Physiol Endocrinol Metab* **294**, E307-315

41. Karyo, R., Eskira, Y., Pinhasov, A., Belmaker, R., Agam, G., and Eldar-Finkelman, H. (2010) Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. *Mol Cell Neurosci* **45**, 449-455

42. Leng, S., Zhang, W., Zheng, Y., Liberman, Z., Rhodes, C. J., Eldar-Finkelman, H., and Sun, X. J. (2010) Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. *J Endocrinol* **206**, 171-181

43. Watson, R. L., Spalding, A. C., Zielske, S. P., Morgan, M., Kim, A. C., Bommer, G. T., Eldar-Finkelman, H., Giordano, T., Fearon, E. R., Hammer, G. D., Lawrence, T. S., and Ben-Josef, E. (2010) GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. *Neoplasia* **12**, 357-365

44. Alon, L. T., Pietrokovski, S., Barkan, S., Avrahami, L., Kaidanovich-Beilin, O., Woodgett, J. R., Barnea, A., and Eldar-Finkelman, H. (2011) Selective loss of glycogen synthase kinase-3alpha in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation. *FEBS Lett* **585**, 1158-1162

45. Azoulay-Alfaguter, I., Yaffe, Y., Licht-Murava, A., Urbanska, M., Jaworski, J., Pietrokovski, S., Hirschberg, K., and Eldar-Finkelman, H. (2011) Distinct molecular regulation of glycogen synthase kinase-3alpha isozyme controlled by its N-terminal region: functional role in calcium/calpain signaling. *J Biol Chem* **286**, 13470-13480

46. Monte, F. L., Kramer, T., Bolander, A., Plotkin, B., Eldar-Finkelman, H., Fuertes, A., Dominguez, J., and Schmidt, B. (2011) Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. *Bioorg Med Chem Lett* **21**, 5610-5615

47. Shruster, A., Eldar-Finkelman, H., Melamed, E., and Offen, D. (2011) Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid beta-peptide. *J Neurochem* **116**, 522-529

48. Lo Monte, F., Kramer, T., Gu, J., Anumala, U. R., Marinelli, L., La Pietra, V., Novellino, E., Franco, B., Demedts, D., Van Leuven, F., Fuertes, A., Dominguez, J. M., Plotkin, B., Eldar-Finkelman, H., and Schmidt, B. (2012) Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3alpha. *J Med Chem* **55**, 4407-4424

49. Avrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D., and Eldar-Finkelman, H. (2013) Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. *J Biol Chem* **288**, 1295-1306

50. Beurel, E., Kaidanovich-Beilin, O., Yeh, W. I., Song, L., Palomo, V., Michalek, S. M., Woodgett, J. R., Harrington, L. E., Eldar-Finkelman, H., Martinez, A., and Jope, R. S. (2013) Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. *J Immunol* **190**, 5000-5011

51. La Pietra, V., La Regina, G., Coluccia, A., Famiglini, V., Pelliccia, S., Plotkin, B., Eldar-Finkelman, H., Brancale, A., Ballatore, C., Crowe, A., Brunden, K. R., Marinelli, L., Novellino, E., and Silvestri, R. (2013) Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3beta inhibitors. *J Med Chem* **56**, 10066-10078

52. Lo Monte, F., Kramer, T., Gu, J., Brodrecht, M., Pilakowski, J., Fuertes, A., Dominguez, J. M., Plotkin, B., Eldar-Finkelman, H., and Schmidt, B. (2013) Structure-based optimization of oxadiazole-based GSK-3 inhibitors. *Eur J Med Chem* **61**, 26-40

53. Aloni, E., Shapira, M., Eldar-Finkelman, H., and Barnea, A. (2015) GSK-3beta Inhibition Affects Singing Behavior and Neurogenesis in Adult Songbirds. *Brain Behav Evol* **85**, 233-244

54. Azoulay-Alfaguter, I., Elya, R., Avrahami, L., Katz, A., and Eldar-Finkelman, H. (2015) Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. *Oncogene* **34**, 4613-4623

55. Licht-Murava, A., Paz, R., Vaks, L., Avrahami, L., Plotkin, B., Eisenstein, M., and Eldar-Finkelman, H. (2016) A unique type of GSK-3 inhibitor brings new opportunities to the clinic. *Sci Signal* **9**, ra110

56. Grieco, S. F., Cheng, Y., Eldar-Finkelman, H., Jope, R. S., and Beurel, E. (2017) Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. *Prog Neuropsychopharmacol Biol Psychiatry* **72**, 49-54

57. Grieco, S. F., Velmeshev, D., Magistri, M., Eldar-Finkelman, H., Faghihi, M. A., Jope, R. S., and Beurel, E. (2017) Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. *World J Biol Psychiatry* **18**, 445-456

58. Pardo, M., Cheng, Y., Velmeshev, D., Magistri, M., Eldar-Finkelman, H., Martinez, A., Faghihi, M. A., Jope, R. S., and Beurel, E. (2017) Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. *JCI Insight* **2**, e91782

59. Avrahami, L., Paz, R., Dominko, K., Hecimovic, S., Bucci, C., and Eldar-Finkelman, H. (2020) GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways. *Cell Signal* **71**, 109597

60. Rippin, I., Khazanov, N., Shirley Ben, J., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., and Eldar-Finkelman, H. (2020) Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site. *Int J Mol Sci* **21**

61. Rippin, I., Bonder, K., Joseph, S., Sarsor, A., Vaks, L., and Eldar-Finkelman, H. (2021) Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease. *Neurobiol Dis* **154**, 105336

62. Moaraf, S., Rippin, I., Terkel, J., Eldar-Finkelman, H., and Barnea, A. (2022) GSK-3beta Inhibition in Birds Affects Social Behavior and Increases Motor Activity. *Front Physiol* **13**, 881174

63. Sheinboim, D., Parikh, S., Manich, P., Markus, I., Dahan, S., Parikh, R., Stubbs, E., Cohen, G., Zemser-Werner, V., Bell, R. E., Ruiz, S. A., Percik, R., Brenner, R., Leibou, S., Vaknine, H., Arad, G., Gerber, Y., Keinan-Boker, L., Shimony, T., Bikovski, L., *et al.* (2022) An Exercise-Induced Metabolic Shield in Distant Organs Blocks Cancer Progression and Metastatic Dissemination. *Cancer Res* **82**, 4164-4178

64. Elkoshi, N., Parikh, S., Malcov-Brog, H., Parikh, R., Manich, P., Netti, F., Maliah, A., Elkoshi, H., Haj, M., Rippin, I., Frand, J., Perluk, T., Haiat-Factor, R., Golan, T., Regev-Rudzki, N., Kiper, E., Brenner, R., Gonen, P., Dror, I., Levi, H., Hameiri, O., Cohen-Gulkar, M., Eldar-Finkelman, H., Ast, G., Nizri, E., Ziv, Y., Elkon, R., Khaled, M., Ebenstein, Y., Shiloh, Y., and Levy, C. (2023) Ataxia Telangiectasia Mutated Signaling Delays Skin Pigmentation upon UV Exposure by Mediating MITF Function toward DNA Repair Mode. *J Invest Dermatol* **143**, 2494-2506 e2494

65. Farfara, D., Sooliman, M., Avrahami, L., Royal, T. G., Amram, S., Rozenstein-Tsalkovich, L., Trudler, D., Blanga-Kanfi, S., Eldar-Finkelman, H., Pahnke, J., Rosenmann, H., and Frenkel, D. (2023) Physiological expression of mutated TAU impaired astrocyte activity and exacerbates beta-amyloid pathology in 5xFAD mice. *J Neuroinflammation* **20**, 174

66. Wittenstein, A., Caspi, M., Rippin, I., Elroy-Stein, O., Eldar-Finkelman, H., Thoms, S., and Rosin-Arbesfeld, R. (2023) Nonsense mutation suppression is enhanced by targeting different stages of the protein synthesis process. *PLoS Biol* **21**, e3002355

**Reviews**

67. Eldar-Finkelman, H. (2002) Glycogen synthase kinase 3: an emerging therapeutic target. *Trends Mol Med* **8**, 126-132

68. Gurwitz, D., and Eldar-Finkelman, H. (2001) Monitor and Molecules. *Drug Discov Today* **6**, 1072-1073

69. Kaidanovich, O., and Eldar-Finkelman, H. (2002) The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. *Expert Opin Ther Targets* **6**, 555-561

70. Eldar-Finkelman, H., and Ilouz, R. (2003) Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment. *Expert Opin Investig Drugs* **12**, 1511-1519

71. Kaidanovich-Beilin, O., and Eldar-Finkelman, H. (2006) Peptides targeting protein kinases: strategies and implications. *Physiology (Bethesda)* **21**, 411-418

72. Eldar-Finkelman, H., and Eisenstein, M. (2009) Peptide inhibitors targeting protein kinases. *Curr Pharm Des* **15**, 2463-2470

73. Eldar-Finkelman, H., Licht-Murava, A., Pietrokovski, S., and Eisenstein, M. (2010) Substrate competitive GSK-3 inhibitors - strategy and implications. *Biochim Biophys Acta* **1804**, 598-603

74. Eldar-Finkelman, H., and Martinez, A. (2011) GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. *Front Mol Neurosci* **4**, 32

75. Licht-Murava, A., Plotkin, B., Eisenstein, M., and Eldar-Finkelman, H. (2011) Elucidating substrate and inhibitor binding sites on the surface of GSK-3beta and the refinement of a competitive inhibitor. *J Mol Biol* **408**, 366-378

76. Licht-Murava, A., and Eldar-Finkelman, H. (2012) Exploiting substrate recognition for selective inhibition of protein kinases. *Curr Pharm Des* **18**, 2914-2920

77. Avrahami, L., and Eldar-Finkelman, H. (2013) GSK-3 and lysosomes meet in Alzheimer's disease. *Commun Integr Biol* **6**, e25179

78. Avrahami, L., Licht-Murava, A., Eisenstein, M., and Eldar-Finkelman, H. (2013) GSK-3 inhibition: achieving moderate efficacy with high selectivity. *Biochim Biophys Acta* **1834**, 1410-1414

79. Arciniegas Ruiz, S. M., and Eldar-Finkelman, H. (2021) Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward. *Front Mol Neurosci* **14**, 792364

80. Rippin, I., and Eldar-Finkelman, H. (2021) Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration. *Cells* **10**

81. Arciniegas Ruiz, S., Rippin, I., and Eldar-Finkelman, H. (2022) Prospects in GSK-3 Signaling: From Cellular Regulation to Disease Therapy. *Cells* **11**